Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $10,313.31 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 201 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $51.31, for a total value of $10,313.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

William Richard White also recently made the following trade(s):

• On Thursday, August 1st, William Richard White sold 201 shares of Disc Medicine stock. The stock was sold at an average price of $43.44, for a total transaction of $8,731.44.

Disc Medicine Stock Down 0.4 %

Shares of NASDAQ:IRON opened at $49.93 on Friday. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -14.77 and a beta of 0.59. The company’s fifty day simple moving average is $47.58 and its 200 day simple moving average is $42.36. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $77.60.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.08. Research analysts expect that Disc Medicine, Inc. will post -4.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Amalgamated Bank increased its holdings in shares of Disc Medicine by 76.9% during the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after acquiring an additional 247 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Disc Medicine during the 2nd quarter worth approximately $129,000. SG Americas Securities LLC boosted its holdings in shares of Disc Medicine by 44.2% in the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock valued at $183,000 after purchasing an additional 1,247 shares in the last quarter. ProShare Advisors LLC acquired a new stake in Disc Medicine in the first quarter valued at about $211,000. Finally, Algert Global LLC bought a new position in shares of Disc Medicine in the second quarter worth about $239,000. Institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on IRON. Wedbush reaffirmed an “outperform” rating and issued a $57.00 price target on shares of Disc Medicine in a research note on Friday, August 9th. BMO Capital Markets reissued an “outperform” rating and issued a $70.00 price target (up previously from $50.00) on shares of Disc Medicine in a report on Monday, June 17th. Wells Fargo & Company started coverage on Disc Medicine in a report on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Disc Medicine in a research report on Monday, September 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $64.13.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.